kiny
Well-known member
- Joined
- Apr 28, 2011
- Messages
- 3,472
1973-1977 discussion on use of Intravenous alimention (bowel rest) in crohn's disease for nutritional support. Subsequent realisation it induces remission in patients with Crohn's disease, but not UC. Crohn's Disease was referred to as Regional Enteritis back then.
DR. FRANCIS C. NANCE (New Orleans, Louisiana):
I think this is a very important study. It represents the tenth anniversary of the
introduction of intravenous hyperalimentation at the University of Pennsylvania, and by definition they have the longest followup of patients managed by this technique.
We have had similar observations in treating patients with inflammatory bowel disease, particularly in patients with regional enteritis and granulomatous colitis. We have been gratified to see resolution of fistulas and what we think is reduction in the severity of
disease.
I'd like to ask Dr. Fitts some specific questions. Have you seen any physical disappearance of the typical granulomatous lesions while the patient is on hyperalimentation? In other words, can this in any way be considered definitive therapy for regional enteritis or granulomatous colitis?
Our own clinical observations are that the patients with regional enteritis and granulomatous lesions respond better than patients with ulcerative colitis. Have you seen patients with florid ulcerative colitis who have not responded at all to hyperalimentation, except in a general increase in their nutritional support?
DR. FRANCIS E. ROSATO (Norfolk, Virginia):
I'd like to thank Dr. Fitts and the other pioneers at the University of Pennsylvania not only for the development of IVH, but for updating their informative and timely experience again.
There are a lot of points in this paper that are worthy of discussion.
First of all, there has been a reported anergy in a fair percentage of patients with chronic inflammatory bowel disease, specifically in their nonreactivity to DNCB, and also in their failure to respond to the mitogen PHA. Along a similar track, there is a body of literature that supports the notion that there is a return to immune competence with intravenous hyperalimentation.
I'm wondering if some of the improvement that one sees in patients with chronic inflammatory bowel disease treated by hyperalimentation might not be due partially, at least, to a restoration to immune competence. Do you have any studies, Dr. Fitts, that would relate to measured immune parameters during the course of treatment?
A last point worth emphasizing is the impressive figure of approximately 40% IVH induced remission, and approximately a 40% rate of non-operative fistula closure with intravenous hyperalimentation.
And to echo Dr. Nance's question, I would ask you again: How long do you persist at the outside in continuing the IVH, in the hope of producing a non-operative remission?
DR. FRANCIS C. NANCE (New Orleans, Louisiana):
I think this is a very important study. It represents the tenth anniversary of the
introduction of intravenous hyperalimentation at the University of Pennsylvania, and by definition they have the longest followup of patients managed by this technique.
We have had similar observations in treating patients with inflammatory bowel disease, particularly in patients with regional enteritis and granulomatous colitis. We have been gratified to see resolution of fistulas and what we think is reduction in the severity of
disease.
I'd like to ask Dr. Fitts some specific questions. Have you seen any physical disappearance of the typical granulomatous lesions while the patient is on hyperalimentation? In other words, can this in any way be considered definitive therapy for regional enteritis or granulomatous colitis?
Our own clinical observations are that the patients with regional enteritis and granulomatous lesions respond better than patients with ulcerative colitis. Have you seen patients with florid ulcerative colitis who have not responded at all to hyperalimentation, except in a general increase in their nutritional support?
DR. FRANCIS E. ROSATO (Norfolk, Virginia):
I'd like to thank Dr. Fitts and the other pioneers at the University of Pennsylvania not only for the development of IVH, but for updating their informative and timely experience again.
There are a lot of points in this paper that are worthy of discussion.
First of all, there has been a reported anergy in a fair percentage of patients with chronic inflammatory bowel disease, specifically in their nonreactivity to DNCB, and also in their failure to respond to the mitogen PHA. Along a similar track, there is a body of literature that supports the notion that there is a return to immune competence with intravenous hyperalimentation.
I'm wondering if some of the improvement that one sees in patients with chronic inflammatory bowel disease treated by hyperalimentation might not be due partially, at least, to a restoration to immune competence. Do you have any studies, Dr. Fitts, that would relate to measured immune parameters during the course of treatment?
A last point worth emphasizing is the impressive figure of approximately 40% IVH induced remission, and approximately a 40% rate of non-operative fistula closure with intravenous hyperalimentation.
And to echo Dr. Nance's question, I would ask you again: How long do you persist at the outside in continuing the IVH, in the hope of producing a non-operative remission?
Last edited: